Merck Remains Committed to RNAi Despite Shuttering Its California Facility | GenomeWeb

By Doug Macron

Merck confirmed late last week that it is closing down its RNAi research-and-development facility in San Francisco, cutting 55 jobs in the process.

However, a Merck spokesperson stressed that the company “continues to invest significantly” in the gene-silencing technology and said that the decision to close the California location was strictly a cost-cutting move.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.